SCHEMBL7121407

SCHEMBL7121407

Cc1c([O])cc(Cl)cc1Cl

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.41
TSHR P16473 4/20 0.38
HSD17B10 Q99714 3/20 0.38
CYP3A4 P08684 1/20 0.38
RECQL P46063 1/20 0.38
RAPGEF4 Q8WZA2 1/20 0.34
KMT2A Q03164 3/20 0.33
HPGD P15428 2/20 0.33
MEN1 O00255 2/20 0.33
AHR P35869 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
NPSR1 Q6W5P4 1/20 0.33
HTT P42858 1/20 0.33
CA1 P00915 1/20 0.32
CA2 P00918 1/20 0.32
CA9 Q16790 1/20 0.32
AKR1C4 P17516 1/20 0.32
AKR1C3 P42330 1/20 0.32
AKR1C2 P52895 1/20 0.32
AKR1C1 Q04828 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL98117 0.80 ALDH1A1 (0.53) ALDH1A1TSHRHSD17B10CYP3A4RECQL
SCHEMBL28514732 0.77 ALDH1A1 (0.50) ALDH1A1TSHRHSD17B10CYP3A4RECQL
SCHEMBL5961682 0.72 ALDH1A1 (0.61) ALDH1A1TSHRHSD17B10CYP3A4RECQL
SCHEMBL1828947 0.72 RAPGEF4 (0.46) ALDH1A1TSHRHSD17B10CYP3A4RECQL
SCHEMBL13253953 0.70 ALDH1A1 (0.38) ALDH1A1TSHRHSD17B10CYP3A4RECQL
SCHEMBL6748353 0.69 GRIN2D (0.33) SMN1; SMN2TP53GRIN2DGRIN3BGRIN1
SCHEMBL4808231 0.69 ERN1 (0.57) ALDH1A1TSHRHSD17B10CYP3A4RECQL
SCHEMBL4954305 0.68 ALDH1A1 (0.41) ALDH1A1TSHRHSD17B10CYP3A4RECQL
SCHEMBL10495441 0.68 ALDH1A1 (0.41) ALDH1A1TSHRHSD17B10CYP3A4RECQL
SCHEMBL7729213 0.68 TSHR (0.56) ALDH1A1TSHRHSD17B10CYP3A4RECQL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030125328-A1 Substituted polycyclic aryl and heteroaryl tertiary-heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity G.D. SEARLE & CO. (US) 2003-07-03 US disclosed
US-6455519-B1 TREATING ATHEROSCLEROSIS AND CARDIOVASCULAR DISORDERS G.D. SEARLE & CO. 2002-09-24 US disclosed
US-6451830-B1 Use of substituted N,N-disubstituted non-fused heterocyclo amino compounds for inhibiting cholesteryl ester transfer protein activity G.D. SEARLE & CO. 2002-09-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030125328-A1 Substituted polycyclic aryl and heteroaryl tertiary-heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity CETP, MTTP, LCAT ALDH1A1 2277/4885TSHR 3307/4885HSD17B10 374/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.